Ophthalmic Res:视网膜疾病预后诊断指标的新技术

2019-09-28 MedSci 网络

瑞士巴塞尔巴塞尔大学眼科学系的Della Volpe-Waizel M等人近日在Ophthalmic Res杂志上发表了一篇文章,系统的回顾了目前视网膜领域最新进展情况。

瑞士巴塞尔巴塞尔大学眼科学系的Della Volpe-Waizel M等人近日在Ophthalmic Res杂志上发表了一篇文章,系统的回顾了目前视网膜领域最新进展情况。

用于测量视网膜功能和结构的新型诊断工具目前正在迅速得到开发,并大量引入临床应用。使用这些信息获取广泛、强有力的诊断措施将是临床试验的终点,这将提供监测干预治疗的机会,并提高安全性,最终来确定视网膜的功效。

为了向研究人员和临床医生、科学家们介绍这些新的诊断工具,欧洲视觉研究所组织了一个研讨会。受邀者对视网膜领域最先进技术的最新进展进行了充分讨论。本综述的重点就是,在已出版文献的背景下介绍研讨会中提及的研究进展。

原文出处:

Della Volpe-Waizel, M., et al., New Technologies for Outcome Measures in Retinal Disease: Review from the European Vision Institute Special Interest Focus Group. Ophthalmic Res, 2019: p. 1-11.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1648522, encodeId=b4651648522bd, content=<a href='/topic/show?id=57ff90e801c' target=_blank style='color:#2F92EE;'>#视网膜疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90780, encryptionId=57ff90e801c, topicName=视网膜疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f87823597669, createdName=xuyong531, createdTime=Tue Jun 02 02:33:00 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739326, encodeId=25d11e39326db, content=<a href='/topic/show?id=908be07412a' target=_blank style='color:#2F92EE;'>#疾病预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70741, encryptionId=908be07412a, topicName=疾病预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b25634523578, createdName=ms2694732865965676, createdTime=Sun Apr 26 18:33:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903841, encodeId=2ccb1903841c0, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon Apr 20 07:33:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689026, encodeId=79ea168902639, content=<a href='/topic/show?id=12d291616b6' target=_blank style='color:#2F92EE;'>#诊断指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91616, encryptionId=12d291616b6, topicName=诊断指标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=157028702540, createdName=ms5353107019656438, createdTime=Wed Mar 18 00:33:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270218, encodeId=28b412e0218b3, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Sep 30 07:33:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541454, encodeId=084c154145439, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Mon Sep 30 07:33:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373359, encodeId=57193e3359dc, content=指标多。, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Sun Sep 29 22:24:22 CST 2019, time=2019-09-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1648522, encodeId=b4651648522bd, content=<a href='/topic/show?id=57ff90e801c' target=_blank style='color:#2F92EE;'>#视网膜疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90780, encryptionId=57ff90e801c, topicName=视网膜疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f87823597669, createdName=xuyong531, createdTime=Tue Jun 02 02:33:00 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739326, encodeId=25d11e39326db, content=<a href='/topic/show?id=908be07412a' target=_blank style='color:#2F92EE;'>#疾病预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70741, encryptionId=908be07412a, topicName=疾病预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b25634523578, createdName=ms2694732865965676, createdTime=Sun Apr 26 18:33:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903841, encodeId=2ccb1903841c0, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon Apr 20 07:33:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689026, encodeId=79ea168902639, content=<a href='/topic/show?id=12d291616b6' target=_blank style='color:#2F92EE;'>#诊断指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91616, encryptionId=12d291616b6, topicName=诊断指标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=157028702540, createdName=ms5353107019656438, createdTime=Wed Mar 18 00:33:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270218, encodeId=28b412e0218b3, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Sep 30 07:33:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541454, encodeId=084c154145439, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Mon Sep 30 07:33:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373359, encodeId=57193e3359dc, content=指标多。, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Sun Sep 29 22:24:22 CST 2019, time=2019-09-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1648522, encodeId=b4651648522bd, content=<a href='/topic/show?id=57ff90e801c' target=_blank style='color:#2F92EE;'>#视网膜疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90780, encryptionId=57ff90e801c, topicName=视网膜疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f87823597669, createdName=xuyong531, createdTime=Tue Jun 02 02:33:00 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739326, encodeId=25d11e39326db, content=<a href='/topic/show?id=908be07412a' target=_blank style='color:#2F92EE;'>#疾病预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70741, encryptionId=908be07412a, topicName=疾病预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b25634523578, createdName=ms2694732865965676, createdTime=Sun Apr 26 18:33:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903841, encodeId=2ccb1903841c0, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon Apr 20 07:33:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689026, encodeId=79ea168902639, content=<a href='/topic/show?id=12d291616b6' target=_blank style='color:#2F92EE;'>#诊断指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91616, encryptionId=12d291616b6, topicName=诊断指标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=157028702540, createdName=ms5353107019656438, createdTime=Wed Mar 18 00:33:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270218, encodeId=28b412e0218b3, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Sep 30 07:33:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541454, encodeId=084c154145439, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Mon Sep 30 07:33:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373359, encodeId=57193e3359dc, content=指标多。, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Sun Sep 29 22:24:22 CST 2019, time=2019-09-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1648522, encodeId=b4651648522bd, content=<a href='/topic/show?id=57ff90e801c' target=_blank style='color:#2F92EE;'>#视网膜疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90780, encryptionId=57ff90e801c, topicName=视网膜疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f87823597669, createdName=xuyong531, createdTime=Tue Jun 02 02:33:00 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739326, encodeId=25d11e39326db, content=<a href='/topic/show?id=908be07412a' target=_blank style='color:#2F92EE;'>#疾病预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70741, encryptionId=908be07412a, topicName=疾病预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b25634523578, createdName=ms2694732865965676, createdTime=Sun Apr 26 18:33:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903841, encodeId=2ccb1903841c0, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon Apr 20 07:33:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689026, encodeId=79ea168902639, content=<a href='/topic/show?id=12d291616b6' target=_blank style='color:#2F92EE;'>#诊断指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91616, encryptionId=12d291616b6, topicName=诊断指标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=157028702540, createdName=ms5353107019656438, createdTime=Wed Mar 18 00:33:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270218, encodeId=28b412e0218b3, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Sep 30 07:33:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541454, encodeId=084c154145439, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Mon Sep 30 07:33:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373359, encodeId=57193e3359dc, content=指标多。, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Sun Sep 29 22:24:22 CST 2019, time=2019-09-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1648522, encodeId=b4651648522bd, content=<a href='/topic/show?id=57ff90e801c' target=_blank style='color:#2F92EE;'>#视网膜疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90780, encryptionId=57ff90e801c, topicName=视网膜疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f87823597669, createdName=xuyong531, createdTime=Tue Jun 02 02:33:00 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739326, encodeId=25d11e39326db, content=<a href='/topic/show?id=908be07412a' target=_blank style='color:#2F92EE;'>#疾病预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70741, encryptionId=908be07412a, topicName=疾病预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b25634523578, createdName=ms2694732865965676, createdTime=Sun Apr 26 18:33:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903841, encodeId=2ccb1903841c0, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon Apr 20 07:33:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689026, encodeId=79ea168902639, content=<a href='/topic/show?id=12d291616b6' target=_blank style='color:#2F92EE;'>#诊断指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91616, encryptionId=12d291616b6, topicName=诊断指标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=157028702540, createdName=ms5353107019656438, createdTime=Wed Mar 18 00:33:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270218, encodeId=28b412e0218b3, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Sep 30 07:33:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541454, encodeId=084c154145439, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Mon Sep 30 07:33:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373359, encodeId=57193e3359dc, content=指标多。, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Sun Sep 29 22:24:22 CST 2019, time=2019-09-29, status=1, ipAttribution=)]
    2019-09-30 zutt
  6. [GetPortalCommentsPageByObjectIdResponse(id=1648522, encodeId=b4651648522bd, content=<a href='/topic/show?id=57ff90e801c' target=_blank style='color:#2F92EE;'>#视网膜疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90780, encryptionId=57ff90e801c, topicName=视网膜疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f87823597669, createdName=xuyong531, createdTime=Tue Jun 02 02:33:00 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739326, encodeId=25d11e39326db, content=<a href='/topic/show?id=908be07412a' target=_blank style='color:#2F92EE;'>#疾病预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70741, encryptionId=908be07412a, topicName=疾病预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b25634523578, createdName=ms2694732865965676, createdTime=Sun Apr 26 18:33:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903841, encodeId=2ccb1903841c0, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon Apr 20 07:33:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689026, encodeId=79ea168902639, content=<a href='/topic/show?id=12d291616b6' target=_blank style='color:#2F92EE;'>#诊断指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91616, encryptionId=12d291616b6, topicName=诊断指标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=157028702540, createdName=ms5353107019656438, createdTime=Wed Mar 18 00:33:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270218, encodeId=28b412e0218b3, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Sep 30 07:33:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541454, encodeId=084c154145439, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Mon Sep 30 07:33:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373359, encodeId=57193e3359dc, content=指标多。, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Sun Sep 29 22:24:22 CST 2019, time=2019-09-29, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1648522, encodeId=b4651648522bd, content=<a href='/topic/show?id=57ff90e801c' target=_blank style='color:#2F92EE;'>#视网膜疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90780, encryptionId=57ff90e801c, topicName=视网膜疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f87823597669, createdName=xuyong531, createdTime=Tue Jun 02 02:33:00 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739326, encodeId=25d11e39326db, content=<a href='/topic/show?id=908be07412a' target=_blank style='color:#2F92EE;'>#疾病预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70741, encryptionId=908be07412a, topicName=疾病预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b25634523578, createdName=ms2694732865965676, createdTime=Sun Apr 26 18:33:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903841, encodeId=2ccb1903841c0, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon Apr 20 07:33:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689026, encodeId=79ea168902639, content=<a href='/topic/show?id=12d291616b6' target=_blank style='color:#2F92EE;'>#诊断指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91616, encryptionId=12d291616b6, topicName=诊断指标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=157028702540, createdName=ms5353107019656438, createdTime=Wed Mar 18 00:33:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270218, encodeId=28b412e0218b3, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Sep 30 07:33:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541454, encodeId=084c154145439, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Mon Sep 30 07:33:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373359, encodeId=57193e3359dc, content=指标多。, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Sun Sep 29 22:24:22 CST 2019, time=2019-09-29, status=1, ipAttribution=)]
    2019-09-29 njwbhuang

    指标多。

    0

相关资讯

Pract Neurol.:对神经科医生诊断为视网膜疾病的病例进行再研究

英国伦敦神经病学和神经外科医院神经内科的Khaleeli Z和英国圣托马斯医院医学眼科的Tucker WR近日在Pract Neurol发表了一项工作,对神经科医生诊断为视神经病变或其他神经疾病的案例,通过眼科医生再进行诊断等形式进行了研究。

Expert Rev Med Devices:基于光学相干断层扫描血管造影术(OCTA)的视网膜疾病血液流速检测技术

美国波士顿塔夫茨医疗中心新英格兰眼科中心的Arya M和Rashad R等人近日在Expert Rev Med Devices杂志上发表了一篇综述性文章,对基于光学相干断层扫描血管造影术(OCTA)的视网膜疾病血液流速检测技术进行了系统的讨论。

Methods Mol Biol:体内谱系命运追踪技术区分视网膜疾病中的小胶质细胞与招募的单核细胞衍生的巨噬细胞

杜克大学医学院眼科的Reyes NJ和Mathew R等近日在Methods Mol Biol发表了一项重要的工作,他们开发了一套新的试验系统,体内谱系命运追踪技术,能够区分视网膜疾病模型中的小胶质细胞和单核细胞衍生的巨噬细胞这两种细胞类型。

Methods Mol Biol:视网膜疾病的细胞治疗研究进展

美国纽瓦克罗格斯大学医学院眼科学和视觉科学研究所的Zarbin M近日在Methods Mol Biol发表了一篇综述,作者系统的阐述了眼科疾病的细胞治疗发展现状。

Obstet Gynecol:子痫前期孕妇更容易发生视网膜疾病

子痫前期,特别严重的或是早发型子痫前期、妊娠后几十年母亲视网膜疾病发生高风险相关。

Eur J Neurosci:Müller神经胶质细胞在视网膜发育和疾病中的作用

美国马里兰州约翰霍普金斯医学院眼科的Subirada PV近日在Eur J Neurosci发表了一篇综述,对Müller神经胶质细胞的生理功能进行了系统性阐述,并对其MGC在糖尿病视网膜炎症、胶质增生、营养和抗氧化因子的合成及分泌中的作用进行了讨论。